The landscape of POLE variants in colorectal and endometrial tumors: Correlation with microsatellite instability (MSI) and tumor mutation burden (TMB).

Authors

null

Sanjeevani Arora

Fox Chase Cancer Center, Philadelphia, PA

Sanjeevani Arora , Joanne Xiu , Davendra Sohal , Emil Lou , Richard M. Goldberg , Benjamin A. Weinberg , Axel Grothey , W. Michael Korn , Mohd Khushman , Anthony Frank Shields , John Marshall , Michael J. Hall

Organizations

Fox Chase Cancer Center, Philadelphia, PA, Caris Life Sciences, Phoenix, AZ, Cleveland Clinic, Cleveland, OH, University of Minnesota School of Medicine, Minneapolis, MN, West Virginia University Cancer Institute, Morgantown, WV, Georgetown University Medical Center, Washington, DC, West Cancer Center, Germantown, TN, Mitchell Cancer Institute, Mobile, AR, Karmanos Cancer Institute, Wayne State University, Detroit, MI, Georgetown University, Washington, DC

Research Funding

No funding received
None

Background: Polymerase epsilon (POLE) is a major replicative DNA polymerase. Somatic POLE pathogenic variants (PV) are prevalent in endometrial cancer (EC) and in germline predispose to colorectal cancer (CRC), EC, and possibly other cancers (CA). PVs in the exonuclease domain (ExoD) [amino acid (AA) 268-471] lead to CAs with exceptionally high TMB. PV and uncertain variants (VUS) outside ExoD are sometimes concurrent with an ExoD PV and/or MSI. We hypothesized that the presence of non-ExoD variants may further increase POLE-associated mutation rate and tumor mutational burden. Methods: We retrospectively examined 1870 CRC and 4481 EC genomic profiles conducted by Caris Life Sciences (6/2016-6/2019). All patients had a 592-targeted gene somatic panel. Profiles with a POLE variant (PV or VUS) were analyzed. Median TMB (TMB, in mutations/megabase) was dichotomized to low/intermed ( < 17) vs high (>17). Tumors were grouped by: single ExoD PV, ExoD PV plus another variant (PV or VUS), or no ExoD PV. Known CRC/EC ExoD PV drivers were identified (Campbell et al, Cell 2017): D275G, P286R, S297F/Y, F367C/L/V, V411L, L424F, P436R/S/Y, M444K/L, A456P, S459F/Y, S461L/P, A465V. Kruskal-Wallis and chi-square tests were used. Results: Overall 4.5% CRC (80/1870) and 6.5% EC (303/4481) samples had POLE variants (Table). High TMB was seen in 56.3% CRC and 53.3% EC. In both CRC/ECs, TMB was higher in tumors with an ExoD PV and a 2nd variant compared to those with a solitary ExoD PV or no ExoD PV (both p < 0.001). MSI was more prevalent in CRC and EC with high TMB but no ExoD PV vs those with either high TMB and an ExoD PV, or low/intermed TMB and no ExoD PV (both p < 0.001). In both CRC/ECs, several ExoD PV associated with very high TMB when non-ExoD regions of POLE contained recurrent variant clusters: AA 1906 (TMB 225); AA 1826-7 (TMB 243); AA 1380-2 (TMB 229). Conclusions: In CRC/ECs, POLE ExoD PV and MSI appear to drive TMB in distinct and largely non-overlapping ways. Non-ExoD POLE variants may synergize with ExoD PVs to further increase mutation rates.

TumorTMBMSI
ExoD PV +2nd variantExoD PV aloneNo ExoD PVTotalHigh TMB, no ExoD PV
N
(%)
High TMB, + ExoD PV
N
(%)
Low/int TMB, no ExoD PV
N
(%)
Total


N
(%)
CRC9/10A
(90)
3/35%
(9)
0/35%
(0)
12/80
(15)
N (%)26 (33)9 (11)45 (56)80
Median TMB
[range]
251
[94-461]
112*
[51-133]
9*
[3-67]
45
[3-461]
EC57/66B
(86)
18/95^
(19)
39/142^
(27)
114/303 (38)
N (%)51 (17)44 (14)208 (69)303
Median TMB
[range]
243
[81-520]
61#
[21-314]
11#
[3-213]
19
[3-520]

251[ref] *p < 0.001; 243[ref] #p < 0.001 A[ref] %p < 0.001; B[ref] ^p < 0.001

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Publication Only

Session Title

Publication Only: Cancer Prevention, Risk Reduction, and Genetics

Track

Prevention, Risk Reduction, and Genetics

Sub Track

Cancer Genetics

Citation

J Clin Oncol 38: 2020 (suppl; abstr e13538)

DOI

10.1200/JCO.2020.38.15_suppl.e13538

Abstract #

e13538

Abstract Disclosures

Similar Abstracts

First Author: McKayla J Riggs

First Author: Marija Stojovska

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Tumor mutation burden in colorectal cancers with POLE exonuclease and non-exonuclease domain variants.

First Author: Salena Ringenbach

First Author: Hui WANG